- Financial Times•19 hours ago
Drugs that selectively destroy cancer cells by destabilising their DNA will be developed in a £6m project funded by the Wellcome Trust at the University of Sussex, in collaboration with AstraZeneca. The ...
- Reuters•5 days ago
Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of their medicines to governments and insurers, though they need to tread carefully on data privacy. GlaxoSmithKline, AstraZeneca and Novartis are all chasing the opportunity via deals with device firms including U.S.-based Propeller Health and Australian-listed Adherium, as well as technology players like Qualcomm.
|Bid||4,660.50 x 20700|
|Ask||4,661.50 x 15300|
|52wk Range||3,680.00 - 4,687.50|
|Day's Range||4,593.43 - 4,687.50|
|Avg Vol (3m)||2,608,685|
As of 6:44 AM EDT. LSE Delayed Price. Market open.